Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on March 21, 2019. Unique to the medical and biotech communities, the investor conference focuses on fast-paced, concise presentations from more than 35 companies, consolidated to a one-day conference while allowing opportunities for one-on-one partnering with venture and strategic investors. Genprex’s presentation is scheduled for Thursday, March 21, at 2:30-2:45 p.m. EDT in the Main Bar Room of the Metropolitan Club, One East 60th Street, New York, NY 10022. “I’m looking forward to attending Cell & Gene Therapy Investor Day for the first time, with the opportunity to share information about Genprex’s mission and our gene therapy technologies,” Genprex President and COO Julien Pham, MD, MPH said in the news release. “With a wide array of companies and industry leaders all presenting in a single day, this conference enables us and the investment community to take the pulse of where the industry is heading. It is an incredible honor to be a part of this event.”
To view the full press release, visit http://ibn.fm/BhatA
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.